Literature DB >> 33508384

miR24-3p activity after delivery into pancreatic carcinoma cell lines exerts profound tumor-inhibitory effects through distinct pathways of apoptosis and autophagy induction.

Hannes Borchardt1, Alexander Ewe1, Markus Morawski2, Ulrike Weirauch1, Achim Aigner3.   

Abstract

Pancreatic cancer is among the most detrimental tumors, with novel treatment options urgently needed. The pathological downregulation of a miRNA in tumors can lead to the overexpression of oncogenes, thus suggesting miRNA replacement as novel strategy in cancer therapy. While the role of miR24 in cancer, including pancreatic carcinoma, has been described as ambiguous, it may hold great promise and deserves further studies. Here, we comprehensively analyze the effects of miR24-3p replacement in a set of pancreatic carcinoma cell lines. Transfection of miR24-3p mimics leads to profound cell inhibition in various 2D and 3D cell assays, based on the induction of apoptosis, autophagy and ROS. Comprehensive analyses of miR24-3p effects on the molecular level reveal the transcriptional regulation of several important oncogenes and oncogenic pathways. Based on these findings, miRNA replacement therapy was preclinically explored by treating tumor xenograft-bearing mice with miR24-3p mimics formulated in polymeric nanoparticles. The obtained tumor inhibition was associated with the induction of apoptosis and necrosis. Taken together, we identify miR24-3p as powerful tumor-inhibitory miRNA for replacement therapy, and describe a complex network of oncogenic pathways affected by miR24.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Pancreatic cancer; miR24; miRNA mimic; miRNA replacement therapy

Mesh:

Substances:

Year:  2021        PMID: 33508384     DOI: 10.1016/j.canlet.2021.01.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

Review 1.  Non-coding RNAs associated with autophagy and their regulatory role in cancer therapeutics.

Authors:  Surbhi Kumari Barnwal; Hrushikesh Bendale; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-05-10       Impact factor: 2.742

2.  MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer.

Authors:  Yuanzhou Zhang; Shunshun Liang; Bowen Xiao; Jingying Hu; Yechun Pang; Yuling Liu; Juan Yang; Junpin Ao; Lin Wei; Xiaoying Luo
Journal:  Cell Death Dis       Date:  2022-03-22       Impact factor: 8.469

3.  The role of miR-145-5p in esophageal squamous cell carcinoma tumor-associated macrophages and selection of immunochemotherapy.

Authors:  Junhong Lin; Sikai Wu; Kanghao Zhu; Jian Zhang; Xiaoshun Shi; Jianfei Shen; Jianfeng Xu
Journal:  J Thorac Dis       Date:  2022-07       Impact factor: 3.005

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.